⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL629443 | 0.82 | — | — | |
| Hydrochloric Acid SCHEMBL2714000 | 0.80 | CA12 (0.47) | — | |
| SCHEMBL2538708 | 0.78 | CA12 (0.53) | — | |
| SCHEMBL3432755 | 0.77 | — | — | |
| SCHEMBL29695451 | 0.77 | — | — | |
| SCHEMBL20481226 | 0.77 | CA12 (0.37) | — | |
| SCHEMBL7039452 | 0.77 | CA12 (0.57) | — | |
| SCHEMBL31651587 | 0.77 | CA12 (0.41) | — | |
| SCHEMBL30258970 | 0.77 | CA12 (0.57) | — | |
| Hydrochloric Acid SCHEMBL27935953 | 0.76 | CA12 (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 211 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117024411-B | Isoquinoline as HPK1 inhibitor | 豪夫迈·罗氏有限公司 | 2026-05-19 | — | — | CN | disclosed |
| EP-3911640-B1 | PCSK9 INHIBITORS FOR USE IN THERAPY, ESPECIALLY THE TREATMENT OF CARDIOVASCULAR DISEASE | ASTRAZENECA AB (SE) | 2026-05-13 | — | — | EP | disclosed |
| US-12584120-B2 | PCSK9 inhibitors and methods of use thereof | ASTRAZENECA AB (SE) | 2026-03-24 | — | — | US | disclosed |
| US-12552807-B2 | PCSK9 inhibitors and methods of use thereof | ASTRAZENECA AB (SE) | 2026-02-17 | — | — | US | disclosed |
| US-20260027113-A1 | PHTHALAZINONE BASED MODULATORS FOR THE TREATMENT OF DISEASE | SOLEY THERAPEUTICS INC (US) | 2026-01-29 | — | — | US | disclosed |
| US-12465603-B2 | Phthalazinone based modulators for the treatment of disease | SOLEY THERAPEUTICS, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| EP-4619387-A1 | PHTHALAZINONE BASED MODULATORS FOR THE TREATMENT OF DISEASE | Soley Therapeutics, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| EP-4616913-A2 | GCN2 INHIBITORS AND USES THEREOF | Merck Patent GmbH (DE) | 2025-09-17 | — | — | EP | disclosed |
| EP-3746075-B1 | GCN2 INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2025-09-03 | — | — | EP | disclosed |
| US-20250214977-A1 | STAT6 INHIBITORS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-07-03 | — | — | US | disclosed |
| WO-1992020642-A1 | BIS MONO-AND BICYCLIC ARYL AND HETEROARYL COMPOUNDS WHICH INHIBIT EGF AND/OR PDGF RECEPTOR TYROSINE KINASE | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) | 1992-11-26 | — | — | WO | disclosed |
| US-4855435-A | Pyridyl-substituted benzothiophenes | THE UPJOHN COMPANY (US) | 1989-08-08 | — | — | US | disclosed |
| EP-0103945-B1 | SUBSTITUTED BENZENEDIOLS AND BENZODIOXINS | THE UPJOHN COMPANY (US) | 1988-04-20 | — | — | EP | disclosed |
| US-4611059-A | THROMBOXANE A2(TXA2) SYNTHETASE INHIBITORS | THE UPJOHN COMPANY (US) | 1986-09-09 | — | — | US | disclosed |
| US-4501892-A | Pyridyl benzenediols | THE UPJOHN COMPANY (US) | 1985-02-26 | — | — | US | disclosed |
| US-4495357-A | THROMBOXANE A2 SYNTHETASE INHIBITORS | THE UPJOHN COMPANY (US) | 1985-01-22 | — | — | US | disclosed |
| US-4490531-A | THROMBOXAN INHIBITOR, ANTITUMOR AGENT, HYPOTENSIVE AGENT | THE UPJOHN COMPANY (US) | 1984-12-25 | — | — | US | disclosed |
| US-4455427-A | THROMBOXANE INHIBITORS | THE UPJOHN COMPANY (US) | 1984-06-19 | — | — | US | disclosed |
| EP-0103945-A2 | Substituted benzenediols and benzodioxins | THE UPJOHN COMPANY (US) | 1984-03-28 | — | — | EP | disclosed |
| EP-0069521-A2 | Pyridinyl and imidazolyl derivatives of benzofurans and benzothiophenes | THE UPJOHN COMPANY (US) | 1983-01-12 | — | — | EP | disclosed |